Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies
Open Access
- 15 March 2004
- journal article
- clinical trial
- Published by Elsevier in American Journal of Transplantation
- Vol. 4 (4) , 626-635
- https://doi.org/10.1111/j.1600-6143.2004.00389.x
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsionTransplantation, 2003
- Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation12Transplantation, 2003
- COADMINISTRATION OF NEORAL AND THE NOVEL RAPAMYCIN ANALOG, SDZ RAD, TO RAT LUNG ALLOGRAFT RECIPIENTSTransplantation, 1999
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- LONG-TERM RENAL ALLOGRAFT SURVIVALTransplantation, 1997
- Rapamune (Sirolimus, Rapamycin): An Overview and Mechanism of ActionTherapeutic Drug Monitoring, 1995
- PREDICTING GLOMERULAR FILTRATION RATE AFTER KIDNEY TRANSPLANTATIONTransplantation, 1995
- EARLY VERSUS LATE ACUTE RENAL ALLOGRAFT REJECTIONTransplantation, 1993
- PRECLINICAL EVALUATION OF A NEW POTENT IMMUNOSUPPRESSIVE AGENT, RAPAMYCINTransplantation, 1991
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976